An anonymous director reports

HLS THERAPEUTICS TO HOST Q2 FISCAL 2024 FINANCIAL RESULTS CONFERENCE CALL

HLS Therapeutics Inc. will release its Q2 2024 financial results on Thursday, Aug. 8, 2024. The company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be co-hosted by Craig Millian, chief executive officer, and John Hanna, interim chief financial officer. Slides to accompany management's prepared remarks will be available to view via the webcast.

Conference ID:  58793

Date:  Thursday, Aug. 8, 2024

Time:  8:30 a.m. ET

Traditional dial-in numbers:  1-800-836-8184 or 1-289-819-1350

Taped replay:  1-888-660-6345 or 1-289-819-1450

Replay code:  58793 followed by the number sign

The taped replay will be available for 14 days, and the archived webcast will be available for 365 days.

A link to the live audio webcast of the conference call will also be available on HLS Therapeutics' website. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast.

About HLS Therapeutics Inc.

Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products that address unmet needs in the treatment of psychiatric disorders and cardiovascular diseases. HLS's management team comprises seasoned pharmaceutical executives with a strong record of success in these therapeutic areas and at managing products in each of these life cycle stages.